Ingelheim, Germany, 25 July, 2012 – Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) received Marketing Authorisation from the European Commission for Jentadueto® which combines the DPP-4 inhibitor, linagliptin and metformin in a single tablet. 1 Linagliptin/metformin hydrochloride (HCl) will provide a new, single-tablet treatment option, taken twice-daily, for adults with Type 2 Diabetes. 1
Jentadueto® (linagliptin/metformin hydrochloride) tablets receive approval for the treatment of adults with Type 2 Diabetes in Europe
New treatment will provide a single tablet option for adults who need to reduce their blood sugar - For Non-U.S. and Non-UK Media
Jul 24, 2012
Latest in Home
Ford to Cut Up to 1,000 Jobs at German Plant as EV Demand Lags
September 16, 2025
It's 'Do or Die' for EV Maker Rivian
September 16, 2025
Ford Moving World Headquarters for First Time in 70 Years
September 15, 2025